{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-8995560-leuprolide:v1","objectPathId":"pubmed-pmid-8995560-leuprolide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-8995560-leuprolide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-8995560-leuprolide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-8995560-leuprolide-v1.md"},"story":{"slug":"pubmed-pmid-8995560-leuprolide","version":1,"domain":"Literature metadata","dateInSource":"2013-11-21","sourceCheckedAt":"2026-07-30","publishedAt":"2026-08-13","peptideSlugs":["leuprolide"],"peptides":[{"slug":"leuprolide","url":"https://peptidescanner.com/peptides/leuprolide/"}]},"claims":[{"id":"headline","text":"A phase II study of leuprolide in advanced/recurrent endometrial cancer.","sourceIds":["pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828"]},{"id":"summary","text":"PubMed lists PMID 8995560 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-01 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828"]},{"id":"paragraph-1","text":"PubMed lists PMID 8995560 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1997-01 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828"]}],"sources":[{"id":"pubmed-observation-pmid-8995560-2013-11-21-d245a72c6828","name":"PubMed","sourceClass":"A","title":"A phase II study of leuprolide in advanced/recurrent endometrial cancer. · retained source version 1:2013-11-21:current:d245a72c68285a8a7baed582e1ba5641855eff1aaf78f888759d24d411412bad","url":"https://pubmed.ncbi.nlm.nih.gov/8995560/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"7b4f9c8c4370547b0a07eb08c82d5434ea07f6f3e74fd9179186a0956b34d2df","tierARecordSha256":"b78adfb7b380c9da6d6d4e718936658294003e4acf88451cdc81e2d0689fc94f"},"integrity":{"algorithm":"sha256","contentSha256":"5319603f70bfc59ffe0560d9c115d27bdaf6081b3ad0ea2be96c2c86e9feefc1"}}